[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 501", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 484 0899", "website": "https://dayonebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.", "fullTimeEmployees": 169, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy  Bender M.B.A., Ph.D.", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1048400, "exercisedValue": 0, "unexercisedValue": 64677}, {"maxAge": 1, "name": "Dr. Samuel C. Blackman M.D., Ph.D.", "age": 54, "title": "Co-Founder and Head of R&D", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 740500, "exercisedValue": 0, "unexercisedValue": 21990}, {"maxAge": 1, "name": "Mr. Charles N. York II, M.B.A.", "age": 46, "title": "COO, CFO & Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 760000, "exercisedValue": 0, "unexercisedValue": 24599}, {"maxAge": 1, "name": "Mr. Adam  Dubow", "age": 56, "title": "General Counsel and Chief Compliance Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 608200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Stubenrauch Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jaa  Roberson", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Davy  Chiodin Ph.D., Pharm.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lauren  Merendino M.B.A.", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elly  Barry M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 14.46, "open": 14.97, "dayLow": 14.01, "dayHigh": 14.9795, "regularMarketPreviousClose": 14.46, "regularMarketOpen": 14.97, "regularMarketDayLow": 14.01, "regularMarketDayHigh": 14.9795, "beta": -1.517, "forwardPE": -7.7880435, "volume": 912955, "regularMarketVolume": 912955, "averageVolume": 1002273, "averageVolume10days": 961730, "averageDailyVolume10Day": 961730, "marketCap": 1408813824, "fiftyTwoWeekLow": 9.76, "fiftyTwoWeekHigh": 18.07, "priceToSalesTrailing12Months": 171.97435, "fiftyDayAverage": 14.112, "twoHundredDayAverage": 14.58875, "currency": "USD", "enterpriseValue": 895931328, "floatShares": 60097483, "sharesOutstanding": 98312200, "sharesShort": 15667396, "sharesShortPriorMonth": 14075501, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.1594, "heldPercentInsiders": 0.19596, "heldPercentInstitutions": 0.87153, "shortRatio": 17.48, "shortPercentOfFloat": 0.1936, "impliedSharesOutstanding": 99204000, "bookValue": 3.498, "priceToBook": 4.0966268, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -167480000, "trailingEps": -1.94, "forwardEps": -1.84, "enterpriseToRevenue": 109.367, "enterpriseToEbitda": -3.12, "52WeekChange": 0.42162693, "SandP52WeekChange": 0.40128052, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DAWN", "underlyingSymbol": "DAWN", "shortName": "Day One Biopharmaceuticals, Inc", "longName": "Day One Biopharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1622122200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a17405a3-1622-35cb-92a5-67defd12b1ed", "messageBoardId": "finmb_704589075", "gmtOffSetMilliseconds": -14400000, "currentPrice": 14.33, "targetHighPrice": 54.0, "targetLowPrice": 24.0, "targetMeanPrice": 39.38, "targetMedianPrice": 40.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 361865984, "totalCashPerShare": 4.123, "ebitda": -287168992, "totalDebt": 190000, "quickRatio": 3.959, "currentRatio": 4.089, "totalRevenue": 8192000, "debtToEquity": 0.062, "revenuePerShare": 0.095, "returnOnAssets": -0.42224, "returnOnEquity": -0.45711, "freeCashflow": -98021624, "operatingCashflow": -177294000, "grossMargins": 0.91370004, "operatingMargins": -14.01453, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]